Rockwell Medical names new president and chief executive officer
23 June 2022 -

Rockwell Medical, Inc. (Nasdaq: RMTI), a US-based biopharmaceutical company, announced on Wednesday that it has named Mark Strobeck, PhD at its new president and chief executive officer, effective 1 July 2022.

Strobeck has more than 20 years of operating, business development, capital raising and investing experience in life sciences for both private and public biotechnology companies. He has served as a managing partner at Aquilo Partners, chief operating officer at Zyla Lifesciences (acquired by Assertio Therapeutics), president and CEO of Corridor Pharmaceuticals (acquired by AstraZeneca), chief business officer of Topaz Pharmaceuticals (acquired by Sanofi Pasteur), chief business officer of Trevena, Inc. and vice president of Business Development at GlaxoSmithKline (GSK). He has served at two venture capital firms, SR One (GSK's formally wholly owned venture capital firm) and EuclidSR Partners.

Strobeck holds a doctorate in biophysics and pharmacology from the University of Cincinnati, has completed his post-doctoral fellowship at the University of Pennsylvania and has a BS from St. Lawrence University.